Healthcare provider profile · identity verified

Holly L. Alexandre, MD

Family Practice · NORTH DARTMOUTH, MA · NPI 1922003334

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	309	29
Atorvastatin Calcium	Atorvastatin Calcium	197	71
Levothyroxine Sodium	Levothyroxine Sodium	190	56
Lisinopril	Lisinopril	190	67
Amlodipine Besylate	Amlodipine Besylate	125	46
Losartan Potassium	Losartan Potassium	119	45
Omeprazole	Omeprazole	95	39
Gabapentin	Gabapentin	88	20
Hydrochlorothiazide	Hydrochlorothiazide	87	37
Metoprolol Succinate	Metoprolol Succinate	85	31
Metformin Hcl	Metformin Hcl	71	27
Simvastatin	Simvastatin	62	25
Buspirone Hcl	Buspirone Hcl	54	13
Fluticasone Propionate	Fluticasone Propionate	53	30
Sertraline Hcl	Sertraline Hcl	53	19
Mirtazapine	Mirtazapine	52	13
Naltrexone Hcl	Naltrexone Hcl	51	14
Rosuvastatin Calcium	Rosuvastatin Calcium	46	16
Venlafaxine Hcl Er	Venlafaxine Hcl	46	suppressed
Ozempic	Semaglutide	43	12
Trazodone Hcl	Trazodone Hcl	43	13
Vivitrol	Naltrexone Microspheres	41	suppressed
Synthroid	Levothyroxine Sodium	38	11
Furosemide	Furosemide	37	16
Topiramate	Topiramate	36	suppressed
Glipizide Er	Glipizide	35	13
Citalopram Hbr	Citalopram Hydrobromide	34	11
Ibuprofen	Ibuprofen	34	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	34	14
Spironolactone	Spironolactone	30	12
Nystatin	Nystatin	29	13
Albuterol Sulfate Hfa	Albuterol Sulfate	28	20
Methylprednisolone	Methylprednisolone	28	22
Duloxetine Hcl	Duloxetine Hcl	27	11
Famotidine	Famotidine	27	suppressed
Carvedilol	Carvedilol	26	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	26	suppressed
Lorazepam	Lorazepam	24	12
Hydroxyzine Hcl	Hydroxyzine Hcl	23	11
Metoprolol Tartrate	Metoprolol Tartrate	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Jardiance	Empagliflozin	22	suppressed
Potassium Chloride	Potassium Chloride	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	19
Atenolol	Atenolol	20	suppressed
Meloxicam	Meloxicam	20	suppressed
Mounjaro	Tirzepatide	20	suppressed
Trulicity	Dulaglutide	20	suppressed
Lactulose	Lactulose	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	11
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Clonazepam	Clonazepam	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Tramadol Hcl	Tramadol Hcl	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Alendronate Sodium	Alendronate Sodium	14	suppressed
Baclofen	Baclofen	14	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	14	suppressed
Diazepam	Diazepam	14	suppressed
Metformin Hcl Er	Metformin Hcl	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Suboxone	Buprenorphine Hcl/Naloxone Hcl	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Zubsolv	Buprenorphine Hcl/Naloxone Hcl	14	suppressed
Bupropion Hcl	Bupropion Hcl	13	suppressed
Premarin	Estrogens, Conjugated	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Fluconazole	Fluconazole	11	11
Humalog Mix 75-25	Insulin Lispro Protamin/Lispro	11	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error